Edition:
United States

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

3.45USD
23 Apr 2018
Change (% chg)

$-0.05 (-1.43%)
Prev Close
$3.50
Open
$3.50
Day's High
$3.55
Day's Low
$3.40
Volume
11,761
Avg. Vol
75,752
52-wk High
$13.00
52-wk Low
$2.80

Chart for

About

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $168.44
Shares Outstanding(Mil.): 48.13
Dividend: --
Yield (%): --

Financials

  IMDZ.OQ Industry Sector
P/E (TTM): -- 185.04 32.78
EPS (TTM): -1.85 -- --
ROI: -44.22 -0.74 13.21
ROE: -44.25 -2.80 15.01

BRIEF-Immune Design Reports Q4 Loss Per Share $0.29

* IMMUNE DESIGN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 14 2018

BRIEF-Immune Design Reports Data Update For Lead Immunotherapy Programs

* IMMUNE DESIGN REPORTS DATA UPDATE FOR LEAD IMMUNOTHERAPY PROGRAMS: IMPROVEMENT IN SURVIVAL FOR CMB305 MONOTHERAPY IN SARCOMA AND INCREASED OBJECTIVE RESPONSES FOR G100/PEMBROLIZUMAB COMBINATION IN FOLLICULAR LYMPHOMA

Mar 12 2018

BRIEF-Immune Design To Report Q4 And Year End 2017 Financial Results And Provide Corporate Update

* IMMUNE DESIGN TO REPORT FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design

* Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​ Source text: (http://bit.ly/2zkI4Ki) Further company coverage:

Nov 06 2017

BRIEF-Immune Design reports Q3 loss per share of $0.52

* IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Nov 01 2017

Earnings vs. Estimates